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Transcriptional activation is a highly synchronized process in eukaryotes that requires a
series of cis- and trans-acting elements at promoter regions. Epigenetic modifications,
such as chromatin remodeling, histone acetylation/deacetylation, and methylation,
have frequently been studied with regard to transcriptional regulation/dysregulation.
Recently however, it has been determined that implications in epigenetic modification
seem to expand into various neurodegenerative disease mechanisms. Impaired
learning and memory deterioration are cognitive dysfunctions often associated with
a plethora of neurodegenerative diseases, including Alzheimer’s disease. Through
better understanding of the epigenetic mechanisms underlying these dysfunctions,
new epigenomic therapeutic targets, such as histone deacetylases, are being
explored. Here we review the intricate packaging of DNA in eukaryotic cells, and
the various modifications in epigenetic mechanisms that are now linked to the
neuropathology and the progression of Alzheimer’s disease (AD), as well as potential
therapeutic interventions.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by significant impairments
in neural synapses and deficiencies in memory. Generally, it is a disease that starts off gradually,
with the most common hallmark symptom being that of short-term memory loss (Burns and Iliffe,
2009). AD deteriorates progressively, with symptoms intensifying over the passage of time. These
symptoms often include extensive memory loss, confusion, difficulty with language, mood swings,
and behavioral issues (Burns and Iliffe, 2009). In most cases, AD progresses to dementia, and
ultimately leads to death, frequently from bronchopneumonia or acute cerebrovascular incidents
(Mölsä et al., 1986).
The classic AD symptoms come alongside debilitating neural atrophy. A depletion in both the
number of neurons and synapses in the brain are characteristic trademarks of AD (Hamos et al.,
1989; Spangenberg and Green, 2017). The deficiency of these key brain cells and nerve connections
often leads to the deterioration of both the temporal and parietal lobes of the brain, as well as parts
of the frontal cortex and cingulate gyrus, as well as brainstem nuclei (Wenk, 2003; Huang et al.,
2007; Braak and Del Tredici, 2012). Research using MRI imaging has shown that patients with AD
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have an actual physical decrease in the size of specific brain
regions as a result of this neuronal loss (Callen et al., 2001).
In addition to neuron and synapse deterioration, patients with
AD have a greater buildup of amyloid plaques and neurofibrillary
tangles in the brain compared to those without AD (Tiraboschi
et al., 2004). The atypical accumulation of these substances is
usually found in the specific areas of the brain associated with
AD, such as the temporal lobe (Bouras et al., 1994). Amyloid
plaques consist of amyloid beta peptides, which are fragments
of the amyloid precursor protein (APP). APP, a transmembrane
protein of the neuronal membrane, is crucial for neuron growth,
repair, and overall function (Turner et al., 2003; Priller et al.,
2006) In AD, the γ-secretase and β-secretase proteolytic cleavage,
unlike α-secretase cleavage, can yield amyloidogenic processing
that can lead to substantial neurpathologies (Kang et al., 1987;
Hooper, 2005; Zhang et al., 2011). For instance, γ-cleavage at C83
or C89 can yield amyloid β (Aβ) peptides, Aβ40 and Aβ42, which
are main constituents of neuropathological plaques in AD brains
(Zhang et al., 2010). These Aβ peptides then form packed deposits
that accrue outside the neuron and surround it Tiraboschi et al.
(2004) and Zhang et al. (2011). While the buildup of these plaque
masses is a clear hallmark of AD, the exact mechanism of how
this accumulation of beta amyloid peptides lead to the pathology
of Alzheimer’s is still unclear (Van Broeck et al., 2007).
Additionally, Tau, a microtubule associated protein, also
accumulates abnormally in the brains of people with AD. While
the tau protein normally functions to stabilize the microtubes
of a cell’s cytoskeleton in its phosphorylated state, tau becomes
hyperphosphorylated in AD. This hyperphosphorylated tau
combines with other threads to form neurofibrillary tangles.
These tangles accrue inside the neuron and greatly impact normal
transport (Hernandez and Avila, 2007). The elevated presence
of both these tangles as well as the above-mentioned amyloid
plaques in the brain have been key indicators of AD.
While the trademark pathology and symptoms of AD are well-
known, the underlying pathways which lead to the disease are
not. Currently, there is no known cure to treat AD (Holtzman
et al., 2011; Lindsley, 2012; Mitra et al., 2019). However, recent
findings indicate that epigenetic modifications are fundamental
in the process of regulating gene expression, particularly for
that of memory (Kosik et al., 2012). Furthermore, AD has been
shown to exhibit an epigenetic blockade, or a widespread decline
in gene expression, that is thought to be influenced by post-
translational histone modifications (Sananbenesi and Fischer,
2009; Gräff et al., 2012). Taken together, it seems that epigenetics
may play a greater role in AD than previously thought. Thus, by
better understanding and studying the impairments of epigenetic
modifications in AD, potential new therapies to treat the disease
can be designed.
Epigenetics is defined as the study of phenotypic changes
that occur from the modification of chromatin without changes
to the actual DNA sequence (Dupont et al., 2009). In order to
understand how epigenetics work, it is important to understand
how DNA is packaged. The genome of a eukaryotic organism
consists of a vast amount of genetic information that must be
stored in the nucleus of each cell (Kornberg, 1974; Peterson
and Laniel, 2004). Since these lengthy DNA molecules are
quite extensive in size, they must be intricately packaged into
higher ordered structures so that they can fit into the relatively
small sized nucleus. In order to accomplish this feat, the DNA
is wound around histone proteins, which associate with each
other via electrostatic and hydrogen interactions, and thus
create the structural unit termed the nucleosome (Cairns, 2009).
A nucleosome consists of the eight core histone proteins, H2A,
H2B, H3, and H4, each of which is present as a pair, and
the DNA that wraps around them (Kornberg and Lorch, 1999;
Pérez-Martìn, 1999; Rando and Winston, 2012). A histone tail
consisting of amino acid chains that are abundant in positively
charged residues, extend from the histone core (Pérez-Martìn,
1999; Martin and Zhang, 2005). There is also an H1 histone
protein, called the linker histone, which associates with the
linker DNA. The linker DNA are the regions of DNA that
exist between nucleosomes after they are structured into the
higher ordered string-like chromatin (Happel and Doenecke,
2009; Harshman et al., 2013). These regions are extremely crucial
for gene expression and regulation (Clapier and Cairns, 2009).
While the higher ordered chromatin structure allows for
the DNA to be tightly packaged and fit into the nucleus, it
produces its own set of issues. Due to the condensed form
of DNA, the promoter region is not as easily accessible for
important cellular processes that require the DNA template
(Smith and Peterson, 2005; Morrison and Shen, 2009). In order
to allow for the promoter to be reachable, nucleosome structure
must be altered or disrupted. The two main categories of
enzymes that specifically target nucleosomes for this purpose
include those that covalently modify histone proteins, such as
those that carry out acetylation, deacetylation, and methylation
and those that hydrolyze ATP to reposition the nucleosome
and thus conduct chromatin remodeling (Margueron et al.,
2005; Smith and Peterson, 2005) (Figure 1). Additionally, there
are other types of histone modifications as well including
that of phosphorylation, ubiquitination, sumoylation, and ADP
ribosylation amongst others.
Acetylation and Deacetylation
The first two types of epigenetic modifications in this review are
that of histone acetylation and deacetylation. Histone acetylases,
or HATs, belong to the category of enzymes that covalently
modify histone proteins by carrying out acetylation on lysine
residues of the core histone tails (Marmorstein, 2001; Roth et al.,
2001). Acetylation is a histone modification often associated
with transcriptional activation. There are two main type of
HATs: Type A and Type B. Type A HATs are localized in the
nucleus and act on the histones associated with the chromatin
(Kornberg and Lorch, 1999; Roth et al., 2001). Type B HATs
however are in the cytoplasm and have been found to act on
freshly synthesized histones that have not yet been associated
with chromatin (Brownell and Allis, 1996; Roth et al., 2001;
Parthun, 2007). Histone deacetylases, or HDACs, are yet another
group of enzymes that covalently modify histone proteins.
While HATs are responsible for neutralizing histone tails by
acetylating lysine residues, HDACs counter their effects by
deacetylating lysine residues. They are therefore associated with
condensing chromatin and gene repression since they directly
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FIGURE 1 | Schematic representation of histone linkage and epigenetic variables that contribute toward the activation and deactivation of genes. Epigenetic
modifications contributing to transcriptional activation include HATs and chromatin remodelers, while HDACs and methylation are more associated with the silences
of gene expression.
revert the histone tails back to their charged status (Pazin and
Kadonaga, 1997). In mammals, there are four classes of histone
deacetylases: classes I, II, III, and IV, and their classification is
based on multiple factors including that of function and DNA
sequence. Depending on the type of HDAC, these deacetylases
can be found both in the nucleus and cytoplasm of the cell
(De Ruijter et al., 2003).
DNA Methylation and Histone
Methylation
While histone acetylation, histone deacetylation, histone
methylation, and chromatin remodeling are all key players in
influencing the epigenetics of an organism, there is yet another
crucial mechanism that is involved in the epigenetic code. DNA
methylation is a process that adds methyl groups to the DNA
structure. Methylation can occur on both cytosine and adenine
bases. While cytosine methylation is quite common in mammals,
it should be noted that methyl groups on adenine bases have
recently been detected in mammalian cells as well (Wu et al.,
2016). Cytosine methylation involves the addition of methyl
groups onto cytosine bases that come directly before guanine
bases on the DNA strand. These are called CpG dinucleotides
(Bird, 1986). Interestingly, recent research has proposed the
importance of DNA methylation in long term memory, a crucial
indication of its potential relationship to AD (Miller and Sweatt,
2007; Day and Sweatt, 2010).
In addition to DNA methylation, histone methylation is
also significant. Histone methyltransferases, or HMTs, are
enzymes that methylate lysine or arginine residues on the
histone tails of histones H3 and H4. HMTs have been linked
to both gene activation and repression. There are two main
families of HMTs, and they are categorized based on the
residues they methylate. The first group consists of histone
lysine methyltransferases, which are the HMTs that methylase
lysine. The second group is made up of protein arginine
methyltransferases, which are responsible for methylating
arginine (Wood and Shilatifard, 2004).
Chromatin Remodelers
While the above three epigenetic mechanisms refer to groups of
enzymes that covalently modify histones, chromatin remodeling
complexes are enzymes that belong to a category all of their
own. These enzyme complexes utilize ATP to reposition the
nucleosome and literally change the dynamics of the chromatin
structure by modifying the connections between the DNA and
histone proteins (Tsukiyama et al., 1999). This process is achieved
through various mechanisms including that of nucleosome
sliding, nucleosome repositioning, and ejection (Fazzio and
Tsukiyama, 2003; Mohrmann and Verrijzer, 2005; Cairns, 2007,
2009; Clapier and Cairns, 2009). There are a number of families
of chromatin remodelers in eukaryotic cells. These include
the families of SWI/SNF, ISW1, NuRD/Mi-2 CHD, INO80,
and SWR1. All of these groups of chromatin remodelers are
similar in their ATPase domain, though they do differ in
their specific remodeling functions (Lusser and Kadonaga, 2003;
Kim et al., 2006).
Due to the significance of epigenetics, and its suggested
involvement in the regulation of gene expression, particularly for
that of memory, it is no wonder that connections to its role in
AD have been made. In this review, we will discuss the epigenetic
dysregulation observed in AD with an emphasis on the potential
of epigenetic therapies to target the neuropathology exhibited as
the disease progresses.
HAT/HDAC IMPLICATIONS IN AD
THERAPEUTICS
Learning and memory involve intricate coordination amongst
a network of various factors and pathways. Long-term memory
and synaptic plasticity are dependent upon activations beyond
the early induction phases of gene expression, which suggests
a wide-ranging potential for epigenetic interplay (Pittenger
and Kandel, 2003). Histone acetylation (and its counterpart,
deacetylation; HATs and HDACs) is one of many epigenetic
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mechanisms now identified as playing a significant role in
long-term potential (LTP) and memory formation, observable
through fear conditioning and spatial memory exercises (Rogan
et al., 1997; Francis et al., 2009).
Hippocampal LTP is an N-methyl-D-aspartate glutamate
receptor-dependent response involving a continuing increase
in synaptic potentiation maintained for longer than 1 h,
which serves as the leading model of synaptic plasticity and
learning in mammalian models (Bliss and Lomo, 1973; Bliss
and Collingridge, 1993). Previous focus on epigenetic factors in
LTP only analyzed methylation, and neglected the significant
impact HATs and HDACs can play, particularly the potential of
HDAC inhibitors (Kazantsev and Thompson, 2008). Although
once regarded for their potential in cancer treatments (Vigushin
and Coombes, 2002), HDAC inhibitors are now regarded as
potential therapeutic targets in AD patients (Xu et al., 2011) with
a wide array of effects (Figure 2).
Alzheimer disease is linked to variants in amyloid-β-protein
precursor (APP), presenilin-1, and presenilin-2 (PS1 and PS2)
genes (Yan et al., 1995; Barglow and Cravatt, 2007), which lead
to neuropathological characteristics of advanced accumulation
of β-amyloid in the brain and the dyruption of synaptic LTP
transmissions (Shankar et al., 2008). Fear conditioning training
using APP/PS1 mice has demonstrated decreased contextual
freezing performance could be restored back to wild type levels
via acute treatment with Trichostatin A (TSA), an HDAC
inhibitor. APP/PS1 chimeric mutant mouse/human transgenes
result in AD phenotypes with β-amyloid plaque deposits
accumulating by 6 months of age (Jankowsky et al., 2003).
In the deficient phenotype mice, hippocampal acetylated H4
levels were approximately half that of WT littermates. HDAC
inhibitor treatment then allowed for the restoration of normal
higher H4 acetyl levels comparable to WT litters. Overall, TSA
treatment rescued H4 acetylation levels, contextual freezing
times, and deficits in hippocampal LTP, as observed through
tetanic stimulations and contextual spatial learning) (Francis
et al., 2009). Further studies have since expanded the HDAC
drugs utilized with similarly significant results. HDACi drugs,
sodium valproic acid, as well as Suberoylanilide hydroxamic acid
(SAHA) and Sodium Butyrate (NaB), have been shown to yield
significantly higher freezing levels in standard electric footshock
freezing fear conditioning compared to their vehicle-treated
(control) mutant APP/PS1 littermates. Treatment restored AD
phenotypes to results that not only were no longer significantly
different from WT littermates, but also were maintained even
weeks later and did not modify any other aspects of behavior not
related to AD pathology, such as exploratory nature or immediate
freezing responses (Kilgore et al., 2010). That longevity of effect
is critical in any therapeutic marketable compound, and has since
been explored to maximize the significant impact that these drugs
can have for patients. Two HDAC inhibitors with longer half-life
and greater Blood Brain Barrier penetration have been developed.
A mercaptoacetamide-based class II HDACi and a hydroxamide-
based class I and II HDACi both decrease β-amyloids in vitro
by reducing gene expression of components and increasing
degradation enzyme gene expression, which ultimately rescued
learning and memory defects in AD mice while decreasing tau
(Sung et al., 2013).
Beyond standard learning deficits, AD can also manifest in
seizures and epileptic episodes, which further instigate cognitive
decline. These seizures increase ∆FosB transcription factor
expression, which in turn recruits HDAC1 in the hippocampus
to suppress c-Fos, a protooncogene known for its role in memory
and synaptic plasticity (Saura et al., 2004). HDAC inhibition
of ∆Fos in APP mutant AD mice via 4-phenylbutyric acid
(Class I HDAC 4-PBA) or MS-275 (inhibitor of HDAC1-3)
has now been shown to reverse the suppression of c-Fos and
thus increases cognition performance in AD mice as observed
with object location memory tasks and hippocampus-dependent
spatial memory tasks (Corbett et al., 2017).
Another transcription factor known to have significance in
AD pathology that may benefit from epigenetic therapeutic
FIGURE 2 | Promising beneficial consequences of HDAC inhibitor treatments observed so far in AD mouse models and post-mortem hippocampal analyses that
can ameliorate neuropathologies.
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interventions is PU.1, which is crucial in the development of
myeloid cells and microglia gene expression (Rustenhoven et al.,
2018). Genome-wide association studies shows that reductions in
PU.1 is a factor in delaying the onset of AD (Huang et al., 2017).
Microarray analyses, RT-qPCR and immunocytochemistry of
PU.1 knock-downs have demonstrated modified AD-associated
microglial genes that are known to be involved in both, innate and
adaptive immunity. Further high-throughput drug screenings
with FDA-approved drugs have yielded the identification of
HDAC-inhibitor, Vorinostat, as efficient in attenuating PU.1
expression in human microglia. Combined results of these
analyses suggested Vorinostat or other HDAC inhibitors that
knockdown PU.1 expression may be useful as potential therapies
that could reduce microglial-mediated immune responses, such
as the excess inflammation observed in AD (Rustenhoven et al.,
2018; Smyth et al., 2018).
Along those lines, it is important to once again emphasize
that AD presents with a wide range of pathologies and thus,
one single target may not suffice to ameliorate the deficits
exhibited across the board. Instead, it may be of greater
promise to explore multitargeting therapeutics. One study
has already exhibited promising results with this technique
by utilizing a single drug, HDACi M344, to affect the
expression of multiple AD-related genes. M344 has been shown
to decrease β-amyloid, phosphorylated tau, β-secretase, and
APOEε4, while it also increased ADAM10, as well as increased
BDNF, MINT2, FE65, SIRT1, REST, ABCA7, BIN1, and APP
trafficking (Volmar et al., 2017). This is significant as β-secretase
(as well as γ-secretase) cleaves Amyloid Precursor Protein
(APP) (Figure 3) in a way that leads to neuropathologies in
AD such as senile plaques, neuroplasticity deficits, and tau
hyperphosphorylation (Nistor et al., 2007). If instead cleavage
is performed by α-secretase (ADAM10), then amyloidogenic
processing is avoided and neuropathology does not present
(Colciaghi et al., 2002). Ultimately, mice treated with M344
exhibited significant cognitive benefits in recognition and spatial
memory testing (Volmar et al., 2017), which demonstrates
the potential to utilize a multitargeting drug to resolve the
polygenic aspect of AD and other neurodegenerative faults.
Another example of how multitargeting can be of value in
AD therapy is the development of a novel “first-in-class” small
molecule called CM-414 that ties HDAC inhibition with PDE5
inhibition, both of which individually have shown auspicious
results (Cuadrado-Tejedor et al., 2017). PDE 5 inhibition
(as seen with vasodilator, Viagra) improves AD phenotype
deficits, as it is a molecule that increases phosphorylation
of CREB, which is a key player in memory. Long-lasting
improvement of synaptic function, CREB phosphorylation, as
well as the reversal of memory deficits, cGMP/PKG/pCREB
signaling deficits, and neuroinflammation, while creating a long-
lasting decrease in Amyloid-beta levels have all been observed
with PDE5 inhibition (Puzzo et al., 2009; Zhang et al., 2013).
PDE5 is ultimately involved in degradation of cGMP in various
locations including brain tissues. The nitric oxide/cGMP/CREB
pathway is critical to learning/memory process, so degradation
of cGMP is implicated in neurodegenerative nature of AD and
drugs inhibiting this degradative process are thus promising
therapeutics (Fiorito et al., 2013). Combining this effectiveness
with the effectiveness of HDAC inhibition can amplify the
benefits for patients. Chronic treatment with the dual inhibitor
CM-414 is capable of rescuing deficient LTPs in APP/PS1
mice, while also reducing the beta-amyloid and phosphorylated
tau levels. Furthermore, CM-414 has been shown to increase
the inactive form of Glycogen synthase kinase-3β (GSK3β)
(Cuadrado-Tejedor et al., 2017). GSK3β is a kinase involved
in microtubule stability and cognition with its connection to
the phosphorylation of tau (Bhat and Budd, 2002) and thus is
associated with the neuropathology of AD (Pláteník et al., 2014).
Additionally, CM-414 has resulted in a decrease in dendritic
spine density on hippocampal neurons, as well as reversed
cognitive deficits observed through fear conditioning testing and
Morris water maze test spatial memory testing as it induces
synaptic gene expression. The in vitro and ex vivo activity of the
drug has been quite promising as it demonstrates how beneficial
it can be to use multiple-target therapies based on the complex
and multifactorial nature of AD neuropathology (Cuadrado-
Tejedor et al., 2017). The only concern with this, however, is
that increased targets means an increased risk of additional side
effects, as has been observed when Vorinostat leads to severe
diarrhea and anorexia when it has been utilized in higher doses
during carcinoma treatment studies (Ree et al., 2010).
Testing expanding beyond mouse models has also been quite
promising with regard to HDAC inhibition drugs. Repeated
treatment of triple transgenic AD mice with RGFP-966 has
been shown to decrease β-amyloid protein levels, reversed the
phosphorylation of tau, and led to improved spatial learning
and memory results as tested by open-field, balance beam,
treadmill, and nest-building behavioral analyses. RGFP-966 was
further shown to increase BDNF expression and decrease tau
phosphorylation and tau acetylation, while also reducing the
neuropathology-inducing β-secretase cleavage of APP. RGFP-966
testing was then expanded to explore the impact when applied
to induce pluripotent stem-cell-derived primary neurons from
AD patients. Although it was a minimal sample size of only
two patients compared to two healthy controls, the results were
promising with a rescue of AD pathology with a decrease in
beta-amyloid accumulation and tau modifications at the diseased
residues of the neurons (Janczura et al., 2018). This further
demonstrates the potential value of HDAC drug therapy for
patients beyond lower organism model results.
Similar significance of epigenetic acetylation patterns has
also been observed in post-mortem human brain tissues,
furthering the promise of HAT/HDAC related drugs in AD
therapeutics. Although HDAC inhibition accounts for the
greater representation of epigenetic therapeutics (meaning lower
acetyl levels tend to be associated with AD neuropathology),
some studies have identified an opposite pattern of epigenetic
modification. Narayan et al. (2015) for instance, utilized
immunolabeling and microarray analyses to demonstrate
increased H3 and H4 acetyl levels in post-mortem AD inferior
temporal gyrus and middle temporal gyrus brain tissues
compared to normal brain tissue, along with compromised
protein degradation mechanisms. Observed differences
significantly correlated with tau, β-amyloid, and ubiquitin
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FIGURE 3 | Amyloidogenic and non-amyloidogenic pathway of APP cleavage via α and β secretases in which the amyloidogenic path yields neuropathological Aβ
plaque peptides critically involved in Alzheimer’s disease.
pathology, as they were only present in areas associated with
pathology and were not identified in the control cerebellum
tissues (Narayan et al., 2015). It should be noted, though,
that post-mortem experiments tend to have smaller sample
sizes than mouse model or cellular based analyses. Despite the
contradiction with mouse models that emphasize deficiencies
in acetylation rather than hyperacetylation, these results still
demonstrate that there clearly exist dysregulations in epigenetic
mechanisms in AD pathologies.
DNA METHYLATION’S POTENTIAL IN AD
THERAPEUTICS
DNA methylation is widely regarded as the most extensively
studied epigenetic modification (Anderson et al., 2012). Although
the focus was previously with regard to cancer (Laird and
Jaenisch, 1996; Baylin and Herman, 2000), methylation has now
taken a position at the forefront of Alzheimer’s disease research,
and may provide insight into new therapeutic approaches to ease
the neuropathology of this crippling disease.
Various studies now examine methylation patterns of
numerous disease-associated genes to determine which genes
have differential patterns upon pathology, either in the form
of hypomethylation or hypermethylation. The same genes are
also frequently studied in more than one bodily location, for
instance hippocampal cells versus blood cells. HOX genes are
of particular interest due to the critical role they play in neural
development as they encode transcription factors responsible
for neural patterning (Philippidou and Dasen, 2013). Recently,
Smith et al. (2018) became the first study to demonstrate
how extensively HOX gene differential methylation can span
in AD patients. Their study has exhibited AD-associated
hypermethylation across an extensive region (48 kb) of the HOXA
cluster using epigenome-wide association in prefrontal cortex
and superior temporal gyrus samples across three independent
cohorts (Smith et al., 2018). In analyzing methylation dynamics
in relation to pathology, one cannot simply apply a one-size-fits-
all methodology, but rather must consider different genes having
different patterns, with hypermethylation silencing of beneficial
protective genes occurring at the same time that hypomethylation
activation of problematic predisposition genes may be occurring.
While hypermethylation of important developmental genes is
observed in this region, so too is hypomethylation of APP, which
results in greater levels of amyloid plaques and neuropathology
(Gasparoni et al., 2018). DNA methylation dysregulation has
also previously been observed in this region in Down syndrome
individuals, which is of interest as many Down syndrome
patients develop AD due to a duplicate of APP in the trisomy
on chromosome 21 (Bacalini et al., 2015). Using post-mortem
brain samples compared to standard aging profiles, Braak stage-
associated methylation variations in both neurons and glia has
further been identified in numerous other genes associated
with AD progression, such as MCF2L, ANK1, MAP2, LRRC8B,
STK32C, and S100B (Gasparoni et al., 2018).
Various aspects of neuropathology are now known to have
links to differential methylation patterns. Immunoreactivity
analyses of entorhinal cortex layer II, known for substantial AD
pathology shows epigenetic dysfunction, particularly significant
decrements (such as in 5-Methylcytosine and 5-methylcytidine)
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in neuronal immunoreactivity of all 10 of the epigenetic
markers and factors studied by Mastroeni et al. (2010),
including PHF1/PS396, DNMT1 (major methyltransferase) and
6 components of MeCP1/MBD2 methylation complex (MTA2,
HDAC1, HDAC2, p66α, RbAp48, and MBD2/3). These results
demonstrate an inverse relationship of DNA methylation
markers and markers for late-stage tangles, as a PHF1 and
PS396 are widely regarded as markers for neurofibrillary tangle
formation (Mastroeni et al., 2010). In addition to the loss of
methylation in neurons being associated with tangle formation,
loss of methylation is also linked to increased expression
of cell cycle genes (Jackson-Grusby et al., 2001; Mattson,
2003) and thus observed decrements in methylation in AD
neurons could be linked to the aberrant re-entry into cell
cycle and apoptosis observed in AD. One study even identified
11,822 hypermethylated CpGs in AD profiles (as well as 6,073
hypomethylated CpGs), with most of the hypermethylated sites
being genes associated with cell-cycle associated processes (such
as regulation of mitosis and phase transitions etc) as well as
wnt-signaling involved in synaptic modulation and cognitive
impairment, whereas hypomethylated sites were identified as
genes involved in transcription factor binding, cofactor binding,
and promoter binding (Gao et al., 2018).
As previously mentioned, location is also noteworthy when
studying AD-related genes. When analyzing to see if genes
associated with early onset AD are differently methylated,
pyrosequencing of AD blood and brain samples have shown that
only RIN3 in blood cells exhibits significant hypomethylation
for 7 CpGs (Boden et al., 2017). RIN3 encodes a potassium-
dependent sodium/calcium exchanger and is associated with cell
signaling and neural development through synapse function and
endocytosis roles by negatively impacting amyloid trafficking
(Giri et al., 2016). In the same study that identified RIN3
hypomethylation, no group-wide significant differences were
observed for late-onset genes PTK2β , ABCA7, SIRT1, or MEF2C
(although 1 CpG of MEF2C did have reduced methylation in
one AD individual) (Boden et al., 2017). This suggests that early
versus late-onset AD pathologies may not permit a universal
epigenetic therapeutics solution. TNF-α, on the other hand, only
shows significant hypomethylation in the cortex samples of AD
patients but not in blood samples, showing that some of the
epigenetic mechanisms being uncovered in AD pathology are
only relevant to brain cells, not blood cells (Kaut et al., 2014),
while others are only observed in blood cells (Boden et al.,
2017). This hypomethylation at the promoter region of tumor
necrosis factor has been linked to a suppression in its activity
due to a lack of transcription factor binding (Pieper et al., 2008),
which then leads to significant deficits in cognitive and synaptic
function, as it triggers an accumulation of amyloid plaques
(Buchhave et al., 2010).
Beyond the cognitive impairment and memory deficits that
most people associate with AD, circadian rhythm disruptions
are also highly prevalent with the majority of AD patients
experiencing modified sleep/wake cycles, thermoregulation
issues, and increased evening confusion (Satlin et al., 1995;
Wu and Swaab, 2007). Upon examination of methylation,
transcription, and expression of BMAL1, which is a known
as a core component of the circadian rhythm clock and
acts as a transcription factor that regulates the firing rate of
hypothalamic suprachiasmatic nucleus neurons (Rudic et al.,
2004), aberrant rhythmic methylation patterns significantly
altering the expression of BMAL1 have been observed in
fibroblasts and post-mortem AD brain samples (Cronin et al.,
2017). The promise of epigenetic therapies thus extends to
circadian cycles and thermoregulation.
In addition to the promising potential of methylation-
related epigenetic therapies for AD neuropathology, these
therapeutic advancements can also aid beyond AD to help
ease the suffering of other neurodegenerative disorder patients.
Significant similarities are observed in differential methylation
studies when AD samples are compared to other disorders
including Bipolar Disorder (BD), Huntington’s, Parkinson’s,
Vascular Dementia, and Lewy-bodies Dementia (Rao et al., 2012;
Smith et al., 2019). Upon testing the CpG methylation of AD
and bipolar disorder associated genes, as well as global DNA
methylation and histone modifications in post-mortem frontal
cortex of 20 patients with these neurodegenerative disorders
(10 of each) AD and BD brains, many epigenetic similarities
were observed. Global DNA hypermethylation and histone
H3 phosphorylation is present in both illnesses, as well as
hypomethylation at the COX-2 promoter, hypermethylation at
the BDNF promoter. CpG methylation of synaptic markers
is present in both illnesses, but there is an increase in
methylation of the synaptophysin promoter in AD only,
while drebin hypermethylation is only present in BD. In
addition to methylation variations, BD and AD present with
an increase in mRNA and protein of neuroinflammatory
markers (IL-1β, TNF-α, astrocytic, and microglial activation
markers) (Rao et al., 2012). Such epigenetic similarities
and the potential of multi-illness therapeutics are promising
ventures to study as both disorders are similarly characterized
with increased neuroinflammatory markers GFAP, CD11b, IL-
1β, increased AA cascade cPLA2IVA, sPLA2IIA and COX2,
and the loss of neurotrophic BDNF and pre-/post-synaptic
synaptophysin and drebin (Rao et al., 2011). Beyond BD, bisulfite
pyrosequencing demonstrates that ANK1 hypermethylation is
not only observed in AD, but is also observed in Huntington’s
disease and Parkinson’s disease, whereas samples with Vascular
Dementia or Lewy bodies Dementia also demonstrated ANK1
hypermethylation, but only when they had coexisting AD-
pathology (Smith et al., 2019). This further demonstrates that
methylation-related epigenetic therapeutics could extend beyond
just ameliorating AD pathologies.
To further explore the epigenetic methylation profile
differences being observed in AD samples, some studies
have even utilized twins to better characterize genetic risks.
Reduced Representation Bisulfite Sequencing of monozygotic
and dizygotic twin pairs to examine whether epigenetic profile
differences associated with AD could be detected in the blood of
participants sharing similar genetic risk profiles shows twin pairs
contain epigenomic differences in AD pathology associated genes
such as ADARB2, including differentially methylated sites in
hippocampal cells rather than just blood cells (Konki et al., 2018).
ADARB2 mutant models are known to demonstrate memory and
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learning deficits, as well as synaptic impairments (Mladenova
et al., 2018). Quantitative immunohistochemistry to study the
levels of DNA methylation and hydroxymethylation in post-
mortem AD patients’ brains has also shown significant decreases
of 5-methylcytosine and 5-hydroxymethylcytosine in AD
patients with similar results observed in an AD twin compared
with the healthy twin. Furthermore, levels of methylation and
hypermethylation had a negative correlation with hippocampal
amyloid plaque levels and neurofibrillary tangles, meaning that
reduced methylation in those same AD patients correlated with
increased amyloid proteins and tangles, although it is unknown
whether it was a causal or consequential event. It should be noted,
though, that sample sizes were low with only 10 post-mortem
AD samples, 10 post-mortem control samples, and only one set
of twins (Chouliaras et al., 2013). Beyond the genetic risk profile,
it is also important to better understand the environmental
lifestyle risk profiles as well to ensure the most comprehensive
knowledge of AD in order to most effectively target it (Eid
et al., 2018). The largest study of DNA methylation-based aging
(biological epigenetic profile age versus actual chronological
age) to date utilized over 5000 individuals to assess genetic and
environmental Alzheimer’s disease risk factors, which allowed
for the identification of significant associations with regard to
lifestyle risk factors rather than genetic factors. Body mass index,
cholesterol levels, socioeconomic status, high blood pressure,
and smoking behavior all were significantly associated with AD
and age acceleration epigenetic profiles (McCartney et al., 2018).
Although differential methylation has been elucidated with
various AD-associated genes, some studies have instead disputed
the idea of DNA methylation involvement in AD progression in
other AD-associated promoters. Nagata et al. (2018), for instance,
provided evidence that there is no differential methylation
observed at the NEP promoter of post-mortem AD brain samples
(Nagata et al., 2018). NEP is a metalloprotease involved in the
degradation of β-amyloid proteins, and known to be deficient
in AD-pathologies where amyloid plaques accumulate (Turner
et al., 2004). The precise downregulation mechanism of NEP
in AD progression still remains to be explained. Overall, the
evidence for methylation playing a role in AD progression and
pathology exceeds any disputes, and thus presents a very strong
case for exploring epigenetic therapeutics in the targeting of AD.
CHROMATIN REMODELERS AND
OTHER HISTONE MODIFICATIONS IN AD
Chromatin Remodelers
While chromatin remodelers play a crucial role in regulating
chromatin, there is currently a lack of information regarding
the position that these enzyme complexes play in AD compared
to that of other epigenetic mechanisms. That being stated,
there does exist some data that shows the connection between
chromatin remodelers and AD. For instance, current research
has revealed that CHD5, a chromatin remodeler belonging to
the CHD family, plays a critical role in Alzheimer’s. While
most remodeling ATPases are expressed throughout the human
body, CHD5 expression is confined to the brain (Potts et al.,
2011). Moreover, the depletion of CHD5 impacts SWI/SNF,
another family of chromatin remodelers. When depleted, CHD5
particularly impacts the subunits of SWI/SNF that are found in
the brain by changing their expression levels. CHD5 has also
been specifically linked to the genes implicated in Alzheimer’s,
as CHD5 has been shown to directly regulate them (Potts et al.,
2011). Thus, a strong connection of the role CHD5 and AD has
been documented.
Additional studies have shown the potential relationship
of other chromatin remodelers with AD as well. Microarray
analysis has shown that “SWI/SNF related, matrix associated,
actin-dependent regulator of chromatin subfamily a, may also
be found to be associated with Alzheimer’s” (Guttula et al.,
2012). Additionally, INO80, Proteasome, and RNAPII machinery
have also been shown to be associated with Alzheimer’s disease,
potentially via RNAPII degradation by INO80 (Poli et al.,




Other histone modifications have been seen to play a role in AD
as well. Phosphorylation is a type of histone modification that can
occur when a phosphate group is added on to the histone tails
of the nucleosome. Research has shown that the H2AX protein
in the nucleosome of astrocytes, a type of supportive nerve cell,
is phosphorylated in response to double strand breakages in the
DNA. When this occurs, there is a conversion of the H2AX
protein into γH2AX. This conversion is specifically found in
greater amounts in astrocytes located in the hippocampal and
cerebral cortex sections of the brain. Interestingly, these regions
are the same areas known to be impacted in AD (Myung et al.,
2008). The above-mentioned studies were performed on brain
tissue acquired from autopsied patients with AD. They indicate
that the phosphorylation found in astrocyte DNA signifies
chromosomal damage, which hinders its role in supporting
surrounding neurons in the area.
Phosphorylation of another core histone protein has been
observed as well. The core histone protein H4 has been shown
to have significantly higher phosphorylation levels on Serine-47
in rats with levels of APP in their neuroblastoma cells compared
to rats that were null in APP for these same types of cells.
Experiments using tissue samples from the brains of AD patients
confirmed these results, as high levels of phosphorylated H4
were observed. These findings are interesting as inhibition of
H4 phosphorylation is now thought to be a potential means
of protection against the pathological progression of AD as
proposed by the authors (Chaput et al., 2016).
Yet another study suggesting the importance of
phosphorylation in AD was published by Anderson and
colleagues. Using transgenic mouse models that had increased
amyloid deposits which mimicked the amyloid pathology that
is characteristic of AD, they studied the phosphorylation of
serine-57 and threonine-58 on H3, a histone greatly regulated
by phosphorylation. Data showed a 40% reduction in serine-
57 phosphorylation and a 45% reduction in threonine-58
phosphorylation in these transgenic mice compared to wild
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type. Additionally, there was a 30% reduction of the doubly
phosphorylated serine-57 and threonine-58 sites. This decline in
phosphorylation is likely thought to result in a more repressed
chromatin structure, which in turn aligns with the epigenetic
blockage exhibited in Alzheimer’s (Anderson et al., 2015). This
again offers the possibility of using phosphorylation inhibition
as a potential targeted therapy for AD. While more research is
needed to determine if such therapies would even be a possibility,
these studies highlight how the dysregulation of phosphorylation
is yet another example of the important role that epigenetic
mechanisms play in AD.
CONCLUSION AND FUTURE
IMPLICATIONS
In this review, we have concentrated on presenting an
overview of the epigenetic dysregulation observed in AD.
While the relationship between the role of impaired epigenetic
modifications in Alzheimer’s has been a relatively recent one, the
ever-increasing amount of research in this field has confirmed
the importance of the connection. As this review has shown,
the overall argument being built is a strong one, as epigenetic
mechanisms, particularly those of DNA methylation and histone
acetylation and deacetylation, show a clear dysregulation in
AD when compared to the norm. It is critical to be able to
target individuals that are most at risk for developing AD
and thus try to proactively treat them as soon as possible.
There are so many variables to be considered that this task
can appear overwhelming. There is no one-and-only cause
for this debilitating disease, but rather a series of interactions
amongst circumstances, the environment, and genomes. Even
within genomes there are multiple variables to consider, as age-
associated genes (Desikan et al., 2017) and epigenetics (Lemche,
2018) can both influence potential buildup of neuropathological
peptides and plaques. Epigenetic profiles can vary throughout
an individual’s lifetime, especially since beyond age, factors such
as stress, smoking, alcohol use, and diet can all affect epigenetic
expressions and neuropathologies (Lövblad et al., 1997; Delgado-
Morales et al., 2017). This may suggest that healthier life-
choices, such as educated dieting and exercise routines, beyond
prescription drug therapeutics may also be of importance in the
treatment and prevention of progression in AD.
Based on the current research, in addition to lifestyle changes,
we have specifically highlighted the potential for epigenetic
therapies that can be used to help target the disease. This is of
great significance, since as of now there are no known cures for
AD that can treat the disease or even delay its process (Holtzman
et al., 2011; Lindsley, 2012; Mitra et al., 2019). Although there
is still some sporadic controversy around epigenetic studies
with regard to the involvement of particular genes in AD, the
overwhelming evidence in support of epigenetic connections
warrants further attention. We believe that with more research
the relationship will only become clearer and the development
of more specific targeted therapies will arise to aid in the
treatment of AD.
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